Badal Pattar

Mr. Badal Pattar

University of Calgary
+3
orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2024 in Circulation: Cardiovascular Quality and Outcomes
Verified
Journal Article
Closed access
CRChantal L. Rytz
Chantal L. Rytz
BPBadal Pattar
Badal Pattar
SMSara J. Mizen
Sara J. Mizen
PLParker Lieb
Parker Lieb
JLJeanna Parsons Leigh
Jeanna Parsons Leigh
SASofia Ahmed
Sofia Ahmed
BACKGROUND: Transgender and nonbinary individuals face substantial cardiovascular health uncertainties. The use of gender-affirming hormone therapy can be used to achieve one’s gender-affirming goals. As self-rated health is an important predictor of health outcomes, an understanding of how this association is perceived by transgender and nonbinary individuals using gender-affirming hormone therapy is required. The objective of this research was to explore transgender and nonbinary individuals’ perceptions of cardiovascular health in the context of using gender-affirming hormone therapy. METHODS: In this qualitative study, English-speaking transgender and nonbinary adults using gender-affirming hormone therapy for 3 months or more were recruited from across Canada using purposive and snowball sampling methods. Semistructured interviews were conducted through videoconference to explore transgender and nonbinary individuals’ perceptions of the association between gender-affirming hormone therapy and cardiovascular health between May and August 2023. Data were transcribed verbatim, and transcripts were analyzed independently by 3 reviewers using thematic analysis. RESULTS: Twenty-one participants were interviewed (8 transgender women, 9 transgender men, and 3 nonbinary individuals; median [range] age, 27 [20–69] years; 80% White participants). Three main themes were identified: cardiovascular health was not a primary concern in the decision-making process with regard to gender-affirming hormone therapy, the improved well-being associated with gender-affirming hormone therapy was felt to contribute to improved cardiovascular health, and health care provider knowledge and attitude facilitate the transition process. CONCLUSIONS: Gender-affirming hormone therapy in transgender and nonbinary individuals is perceived to improve cardiovascular health. Given the positive associations between care aligned with patient priorities, self-rated health, and health outcomes, these findings should be considered as part of shared decision-making and person-centered care.

17 August 2020 in Biomedicines
Verified
Journal Article
Open access
PDF file
CSChunhua Shi
Chunhua Shi
Daiana Alvarez-OlmedoDaiana Alvarez-Olmedo
Daiana Alvarez-Olmedo
YZYuan Zhang
Yuan Zhang
BPBadal Pattar
Badal Pattar
EOEdward R. O'Brien
Edward R. O'Brien
Previously, we demonstrated that Heat Shock Protein 27 (HSP27) reduces the inflammatory stages of experimental atherogenesis, is released by macrophage (MΦ) exosomes and lowers cholesterol levels in atherosclerotic plaques. Recently, we discovered that natural autoantibodies directed against HSP27 enhance its signaling effects, as HSP27 immune complexes (IC) interact at the cell membrane to modulate signaling. We now seek to evaluate the potential role of the HSP27 IC on MΦ exosomal release and cholesterol export. First, in human blood samples, we show that healthy control subjects have 86% more exosomes compared to patients with coronary artery disease (p < 0.0001). Treating human THP-1 MΦ with rHSP27 plus a validated anti-HPS27 IgG antibody increased the abundance of exosomes in the culture media (+98%; p < 0.0001) as well as expression of Flotillin-2, a marker reflective of exosomal release. Exosome cholesterol efflux was independent of Apo-A1. THP-1 MΦ loaded with NBD-labeled cholesterol and treated with the HSP27 IC showed a 22% increase in extracellular vesicles labeled with NBD and a 95% increase in mean fluorescent intensity. In conclusion, exosomal abundance and secretion of cholesterol content increases in response to HSP27 IC treatment, which may represent an important therapeutic option for diseases characterized by cholesterol accumulation.

4 October 2024 in PLOS ONE
Verified
Journal Article
Open access
PDF file
BPBadal Pattar
Badal Pattar
NGNabilah Gulamhusein
Nabilah Gulamhusein
CRChantal L. Rytz
Chantal L. Rytz
KMKeila Turino Miranda
Keila Turino Miranda
LBLauren B. Beach
Lauren B. Beach
SASofia Ahmed
Sofia Ahmed
Background and objective: Transgender and gender-diverse (TGD) persons experience health inequities compared to their cisgender peers, which is in part related to limited evidence informing their care. Thus, we aimed to describe the literature informing care provision of TGD individuals. Data source, eligibility criteria, and synthesis methods: Literature cited by the World Professional Association of Transgender Health Standards of Care Version 8 was reviewed. Original research articles, excluding systematic reviews (n = 74), were assessed (n = 1809). Studies where the population of interest were only caregivers, providers, siblings, partners, or children of TGD individuals were excluded (n = 7). Results were synthesized in a descriptive manner. Results: Of 1809 citations, 696 studies met the inclusion criteria. TGD-only populations were represented in 65% of studies. White (38%) participants and young adults (18 to 29 years old, 64%) were the most well-represented study populations. Almost half of studies (45%) were cross-sectional, and approximately a third were longitudinal in nature (37%). Overall, the median number of TGD participants (median [IQR]: 104 [32, 356]) included in each study was approximately one third of included cisgender participants (271 [47, 15405]). In studies where both TGD and cisgender individuals were included (n = 74), the proportion of TGD to cisgender participants was 1:2 [1:20, 1:1]. Less than a third of studies stratified results by sex (32%) or gender (28%), and even fewer included sex (4%) or gender (3%) as a covariate in the analysis. The proportion of studies with populations including both TGD and cisgender participants increased between 1969 and 2023, while the proportion of studies with study populations of unspecified gender identity decreased over the same time period. Conclusions: While TGD participant-only studies make up most of the literature informing care of this population, longitudinal studies including a diversity of TGD individuals across life stages are required to improve the quality of evidence.

5 February 2025 in BMJ Open
Verified
Journal Article
Open access
NGNabilah Gulamhusein
Nabilah Gulamhusein
BPBadal Pattar
Badal Pattar
SDSandra M Dumanski
Sandra M Dumanski
THTyrone G Harrison
Tyrone G Harrison
SBSonia Butalia
Sonia Butalia
SASofia Ahmed
Sofia Ahmed
Introduction: Cardiovascular disease is the leading cause of death among women worldwide, and hypertension is one of the most prevalent and modifiable risk factors. Parity and gravidity, independent of pregnancy complications, have each been associated with hypertension, although results are conflicting. Therefore, we propose to estimate the association between parity and gravidity with hypertension and blood pressure in a systematic review of the literature. Methods and analysis: A systematic review will be conducted to estimate the association between parity and gravidity and hypertension and blood pressure. Electronic databases (Excerpta Medica Database, Ovid MEDLINE, Cochrane Central Register of Controlled Trials, Cumulative Index to Nursing and Allied Health Literature Plus and Web of Science) will be searched from inception to January 2025. Two investigators will independently screen identified abstracts and select observational cohort studies, case-control studies and randomised controlled trials examining parity or gravidity and hypertension or blood pressure. Extracted data will include study and population characteristics, comorbidities, parity, gravidity, incidence of hypertension and changes in blood pressure, study quality and risk of bias. If there are sufficient data, they will be summarised using random effects meta-analysis to estimate the pooled risk ratio or odds ratio of hypertension. Stratified and subgroup analyses will be used to explore potential sources of heterogeneity. PROSPERO registration number: CRD42024560535.

26 March 2026 in Clinical Journal of the American Society of Nephrology
Verified
Journal Article
Open access
BPBadal Pattar
Badal Pattar
ESEmir Sevinc
Emir Sevinc
TSTayler D. Scory
Tayler D. Scory
MYMaryam Yaqoob
Maryam Yaqoob
MEMeghan J. Elliott
Meghan J. Elliott
THTyrone G. Harrison
Tyrone G. Harrison
Key Points: People with CKD are at high risk of unplanned readmission and death due to multimorbidity and health care complexity. Lower eGFR is strongly associated with 30-day unplanned readmission or death, with congestive heart failure as the most common cause. Targeted, risk-based discharge strategies are needed to reduce readmissions and improve outcomes in CKD populations. Background: People with CKD have higher risk of repeated hospitalization and mortality than the general population. Given many unplanned readmissions may be avoidable, examining risks and reasons for readmission across CKD categories may inform targeted interventions and safer discharge planning. Thus, we estimated the association between eGFR and both readmission and mortality and identified diagnoses for readmission. Methods: Adults discharged from hospitals in Alberta, Canada, from 2005 to 2021 were included. Preadmission eGFR was categorized into eight groups (in ml/min per 1.73 m 2 ): ≥60 (G1–2), 45–59 (G3a), 30–44 (G3b), 15–29 (G4), <15 not on dialysis (G5ND), on dialysis (G5D), prevalent kidney transplant recipients (G1T–5T), and unknown. The primary outcome was unplanned readmission or death within 30 days of discharge. Multivariable logistic regression, accounting for multiple admissions per participant, was used to estimate unadjusted and adjusted odds ratios (aOR) of the primary outcome, using G1–2 as the reference. The results were stratified by age and sex. The type and frequency of each unplanned readmission was also determined. Results: The cohort comprised 2,992,810 admissions among 1,249,248 participants (median [interquartile range] admission per participant: 1 [1–3] admission; age: 61 [47–74] years). Among lower eGFR categories, heart failure was the most common readmission diagnosis, followed by AKI. Relative to G1–2, more impaired eGFR groups had significantly higher odds of the primary outcome, with the highest adjusted odds experienced by the G1T–5T group (aOR, 1.47; 95% confidence interval, 1.12 to 1.93) and G5ND group (aOR, 1.40; 95% confidence interval, 1.34 to 1.47). Stratified analyses showed that individuals younger than 65 years and females with reduced eGFR had higher odds compared with counterparts in the G1–2 reference group. Conclusions: People with severe CKD had the highest risk of hospital readmission, suggesting the need to test interventions in this group to target volume and hemodynamic related readmissions such as postdischarge AKI and heart failure.

16 September 2026 in Clinical Journal of the American Society of Nephrology
Verified
Journal Article
Closed access
BPBadal Pattar
Badal Pattar
SASofia Ahmed
Sofia Ahmed
Was not provided for this article.